- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01312636
Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
October 17, 2014 updated by: Novo Nordisk A/S
A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Congenital FVII Deficiency - Registry for All Treated Patients
This study is conducted in Japan.
The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
36
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan, 1000005
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All subjects with a FVII deficiency to whom activated recombinant human factor VII (NovoSeven®) is administered
Description
Inclusion Criteria:
- Congenital FVII deficiency
- Never been treated with NovoSeven® before
- Patients already in treatment with NovoSeven®
Exclusion Criteria:
- History of hypersensitivity to any of the components in NovoSeven®
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
A
|
Data will be collected at the baseline visit and approximately once a year until end of study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence and/or the appearance of inhibiting antibodies to factor VII and/or therapy-related thrombosis on using NovoSeven® under normal clinical practice conditions
Time Frame: once a year in years 1-4
|
once a year in years 1-4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the treatment evaluation for bleeding episodes
Time Frame: year 1, year 4
|
year 1, year 4
|
To assess the course and outcome of pregnancy in women treated with novoseven
Time Frame: until 1 month after giving birth
|
until 1 month after giving birth
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
March 2, 2011
First Submitted That Met QC Criteria
March 10, 2011
First Posted (Estimate)
March 11, 2011
Study Record Updates
Last Update Posted (Estimate)
October 20, 2014
Last Update Submitted That Met QC Criteria
October 17, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F7HAEM-3862
- U1111-1116-1529 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Bleeding Disorder
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, United Kingdom
-
Novo Nordisk A/SEnrolling by invitationCongenital Bleeding Disorder | Congenital FXIII DeficiencyJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencySpain, United States, Canada, Italy, United Kingdom, Hungary
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom, Israel, United States
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, Austria, Spain, Switzerland, Germany, Canada, France, United Kingdom, Italy, Finland
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding DisorderUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's DiseaseGermany
Clinical Trials on activated recombinant human factor VII
-
Novo Nordisk A/SCompletedTrauma | Acquired Bleeding DisorderUnited States, Canada
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's DiseaseFrance
-
Novo Nordisk A/SCompletedAcquired Bleeding Disorder | Intracerebral HaemorrhageSpain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding DisorderUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BFrance, Israel, Germany
-
Novo Nordisk A/SCompletedOther Haemostasis Disorder | Haemorrhagic CystitisUnited States
-
Novo Nordisk A/STerminatedAcquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary BypassUnited States, Spain, Germany, Sweden, United Kingdom, Argentina, Italy, Brazil, Denmark, France, India, Malaysia, Singapore, South Africa
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsFrance, United Kingdom, Spain, Israel, Poland, Turkey, Hungary
-
Novo Nordisk A/SCompletedCirrhosis | Acquired Bleeding DisorderGermany, United Kingdom, Spain, Taiwan, France, Italy, Austria, Czech Republic, Poland, Denmark, Finland, Hong Kong
-
Novo Nordisk A/SCompletedTrauma | Acquired Bleeding DisorderIndia, Spain, Canada, Finland, Germany, Israel, Italy, Netherlands, Singapore, Switzerland, Taiwan